Introduction {#sec1}
============

Glioma is one of the common types of primary central nervous system (CNS) tumors, accounting for 30% of all CNS tumors, almost 80% of which are considered malignant, and are responsible for the majority of deaths from primary brain tumors \[[@B1]\]. In 2015, the incidence and mortality of glioma in China were approximately 101600 and 61000, respectively, with a ratio of 3:2 for men and women \[[@B2]\]. The incidence of glioma in general increases with age, from 0.9 in children to 12.1 in the elderly \[[@B3]\]. Patients with glioma usually have poor survival rates and unfavorable prognosis. The etiology of glioma remains poorly understood and is attributed to different genetic or environmental factors \[[@B4]\]. Recently, a vast number of studies have reported that genetic factors contribute to the development of glioma, which revealed single-nucleotide polymorphisms (SNPs) in cancer-related genes were associated with glioma susceptibility and prognosis \[[@B5]\].

Mastermind-like transcriptional co-activator 2 (MAML2) is a member of the mastermind-like family of proteins, which is a co-activator of the oncogenic NOTCH signaling pathway \[[@B8]\]. NOTCH signaling activation has been demonstrated to be involved in carcinogenesis, which plays a critical role in cell proliferation, metastasis and epithelial--mesenchymal transition in many diverse solid tumors including glioma \[[@B9],[@B10]\]. Several studies have demonstrated *MAML2* abnormal expression in various cancers, such as mucoepidermoid carcinoma, hidradenoma and breast cancer \[[@B11]\]. These studies have suggested that *MAML2* might be involved in the tumorigenesis and progression of cancers. Based on microarray data of glioma, *MAML2* as a novel gene related to glioma was identified \[[@B14]\]. Additionally, epidemiological studies have confirmed that polymorphisms in *MAML2*, a NOTCH pathway gene, were related to cancer susceptibility and prognosis \[[@B15],[@B16]\]. However, no previous study has investigated the contribution of *MAML2* variants to glioma risk and prognosis.

In this hospital-based case--control study, we aimed to investigate the association of *MAML2* polymorphisms with the susceptibility of glioma, and the role of these polymorphisms in the prognosis of glioma patients among the Chinese Han population.

Materials and methods {#sec2}
=====================

Study subjects {#sec2-1}
--------------

This case--control study recruited 575 glioma patients and 500 cancer-free controls from the Second Affiliated Hospital of Xi'an Jiaotong University. All participants were genetically unrelated ethnic Han Chinese. Patients with primary glioma were newly diagnosed and histopathologically confirmed. The blood samples were collected before radiotherapy and chemotherapy therapies or surgery. The patients who had history of cancer and serious systemic diseases (leukemia, diabetes, cardiovascular and cerebrovascular diseases and genetic diseases) or other diseases were excluded. All the patients were followed up every 3 months. During the follow-up period, overall survival (OS) and progression-free survival (PFS) were measured from diagnosis to death or the last follow-up. The age and gender-matched healthy tumor-free volunteers were recruited from annual checkup visitors of the same hospitals as control subjects. The controls were selected from the skull MRI with a negative diagnosis for glioma, without other cancers or chronic diseases and no diseases related to brain and CNS. Demographic and clinical pathological data were collected through interviewers' administered questionnaires and/or medical records. The institutional ethics committees of the Second Affiliated Hospital of Xi'an Jiaotong University approved the procedures followed in the present study. All procedures involving human participants were in accordance with the Helsinki Declaration. Signed informed consent was obtained from all individuals who participated in the study.

SNPs genotyping {#sec2-2}
---------------

Genomic DNA was extracted from EDTA anticoagulated peripheral blood samples from each subject using a Qiagen DNA Isolation Kit (Qiagen, Valencia, CA, U.S.A.) according to the manufacturer's instructions, and stored at −20°C until additional analysis. *MAML2* mRNA expression analysis in glioma was performed using GEPIA (<http://gepia.cancer-pku.cn/>) datasets. Seven *MAML2* SNPs (rs7107785, rs479825, rs7938889, rs11021499, rs7115578, rs4598633 and rs485842) were selected as candidate SNPs for genotyping in the current study. These SNPs were selected based on a minor allele frequency (MAF) of \>5% in Chinese populations and with a pairwise *r^2^* ≥ 0.80, from the NCBI dbSNP database (<http://www.ncbi.nlm.nih.gov/projects/SNP>) and the 1000 Genomes Project data (<http://www.internationalgenome.org/>). To evaluate the potential function of the selected SNPs, we conducted *in silico* analysis using HaploReg v4.1 (<https://pubs.broadinstitute.org/mammals/haploreg/haploreg.php>) and SNPinfo Web Server (<https://snpinfo.niehs.nih.gov/>). *MAML2* SNPs genotyping was performed Agena MassARRAY system (Agena, San Diego, CA, U.S.A.) in double-blinded \[[@B17],[@B18]\]. The primers used in amplification and single base extension were shown in Supplementary Table S1, which was designed by the MassARRAY Assay Design 3.0 software. For quality control, the call rate of genotyping \>95%, and approximately 10% of the samples were randomly selected for repeated analysis, of which the reproducibility was 100%.

Statistical analyses {#sec2-3}
--------------------

All analyses were performed with the SPSS 18.0 (SPSS Institute, Chicago, IL, U.S.A.) and the PLINK 2.1.7 software. Baseline characteristics were presented as mean ± standard deviation (SD) for continuous data and as number (percentages) for categorical parameters. Variables were compared between the cases and controls using the Chi-squared for gender and the independent samples *t* test for age. Hardy--Weinberg equilibrium (HWE) was evaluated by Pearson's χ^2^ test comparing the expected and observed genotype frequencies of *MAML2* SNPs in the control group. Differences in allele and genotype frequencies between glioma patients and cancer-free controls were also tested with χ^2^ test. The major allele was considered to be the reference allele. To determine the association between genotypes of *MAML2* SNPs and glioma risk, logistic regression analysis was performed to compute odds ratios (ORs) and 95% confidence intervals (CIs), with the adjustment of age and gender. Multiple genetic models (allele, genotype, dominant, recessive and log-additive) were estimated by PLINK software. Kaplan--Meier survival analysis with the log-rank test was used to evaluate the relationship between clinical or genomic factors (*MAML2* polymorphisms) and glioma prognosis. Hazard ratios (HRs) and 95% CIs were calculated from univariate and multivariate Cox proportional hazard regression analyses to evaluate the correlation between *MAML2* polymorphisms and glioma prognosis. All *P*-values were two-sided, and a *P*-value \<0.05 was considered statistically significant.

Results {#sec3}
=======

Subject characteristics {#sec3-1}
-----------------------

Demographic and clinical characteristics of glioma patients and controls are shown in [Table 1](#T1){ref-type="table"}. The patients included 320 males and 255 females with a mean age of 40.53 ± 13.90 years, and the controls included 279 males and 221 females with a mean age of 40.46 ± 18.08 years. No significant difference was observed in age and gender distribution between the two groups (*P*=0.942 and *P*=0.968, respectively). Among all cases, 369 (64.2%) were in grades I--II and 206 (35.8%) in III--IV and 448 (77.9%) with astrocytoma.

###### Characteristics of patients with glioma and controls

                           Characteristics          Cases (*n*=575)   Controls (*n*=500)   *P*
  ------------------------ ------------------------ ----------------- -------------------- ----------
  **Age, years**           Mean ± SD (year)         40.53 ± 13.90     40.46 ± 18.08        0.942^1^
  **Gender**               Male                     320 (55.7%)       279 (55.8%)          0.968^2^
                           Female                   255 (44.3%)       221 (44.2%)          
  **WHO grade**            I--II                    369 (64.2%)                            
                           III--IV                  206 (35.8%)                            
  **Classification**       Astrocytoma              448 (77.9%)                            
                           Others                   127 (22.1%)                            
  **Surgical method**      STR and NTR              183 (31.8%)                            
                           GTR                      392 (68.2%)                            
  **Radiotherapy**         No                       56 (9.7%)                              
                           Conformal radiotherapy   155 (27.0%)                            
                           γ knife                  364 (63.3%)                            
  **Chemotherapy**         No                       341 (58.8%)                            
                           Yes                      237 (41.2%)                            
  **Survival condition**   Survival                 40 (7.0%)                              
                           Lost                     21 (3.6%)                              
                           Death                    514 (89.4%)                            

Abbreviations: GTR, gross-total resection; NTR, near-total resection; STR, subtotal resection; WHO, World Health Organization.

^1^*P*-values were calculated by independent samples *t* test.

^2^*P*-values were calculated by Chi-square tests.

The details of MAML2 SNPs {#sec3-2}
-------------------------

Detailed information about the seven selected SNPs is displayed in Supplementary Table S2. Genotype distribution of all SNPs among controls was in agreement with HWE (*P*\>0.05). *In silico* analysis using HaploReg v4.1 and SNPinfo Web Server, the function of the selected SNPs was successfully predicted to have biological functions (Supplementary Table S2). Furthermore, we extracted *MAML2* expression data between glioma patients and healthy controls from GEPIA database. Supplementary Figure S1 showed that there were significant differences of *MAML2* expression in glioblastoma multiforme and brain lower grade glioma compared with normal tissue (*P*\<0.01). Moreover, the expression of *MAMAL2* was particularly associated with the prognosis of lower grade glioma (log-rank *P*=0.0094, Supplementary Figure S2).

Association between MAML2 SNPs and glioma risk {#sec3-3}
----------------------------------------------

Among the seven *MAML2* SNPs, two SNPs (rs7938889 and rs485842) were found to be significantly related to the risk of glioma by an adjustment for age and gender. The genotype and allele frequencies distribution of rs7938889 and rs485842 and their association with glioma risk are shown in [Table 2](#T2){ref-type="table"}. Subjects with rs7938889 TT genotype were associated with a reduced risk of glioma (TT vs. CC, OR = 0.69, 95%: 0.48--0.99, *P*=0.043; and TT vs. CC-CT, OR = 0.69, 95%: 0.50--0.95, *P*=0.023). Rs485842 polymorphism also displayed a lower risk of developing glioma under allele (OR = 0.81, 95%: 0.67--0.98, *P*=0.032), homozygote (OR = 0.59, 95%: 0.37--0.96, *P*=0.033) and additive (OR = 0.81, 95%: 0.67--0.98, *P*=0.033) models. Additionally, rs7938889 variant had a relationship with decreasing astrocytoma risk under multiple genetic model (allele, OR = 0.82, *P*=0.035; homozygote, OR = 0.61, *P*=0.013; recessive, OR = 0.63, *P*=0.009; and additive, OR = 0.81, *P*=0.027). No statistically significant associations were observed between *MAML2* rs7107785, rs479825, rs11021499, rs7115578 and rs4598633 variants and the risk of glioma.

###### Relationships between *MAML2* polymorphisms and the risk of glioma and astrocytoma

  SNP ID      Model          \>Genotype   \>Control (*n*)   Glioma   Astrocytoma                                                          
  ----------- -------------- ------------ ----------------- -------- ----------------------- ----------- -------- ----------------------- -----------
  rs7938889   Allele         C            551               671      1                                   532      1                       
                             T            449               471      0.86 (0.73--1.02)       0.088       356      **0.82 (0.68--0.99)**   **0.035**
              Genotype       CC           150               183      1                                   148      1                       
                             CT           251               305      1.00 (0.76--1.31)       0.980       236      0.95 (0.71--1.26)       0.714
                             TT           99                83       **0.69 (0.48--0.99)**   **0.043**   60       **0.61 (0.41--0.90)**   **0.013**
              Dominant       CC           150               183      1                                   148      1                       
                             CT-TT        350               388      0.91 (0.70**--**1.18)   0.473       296      0.85 (0.65**--**1.12)   0.252
              Recessive      CC-CT        401               488      1                                   384      1                       
                             TT           99                83       **0.69 (0.50--0.95)**   **0.023**   60       **0.63 (0.44--0.89)**   **0.009**
              Log-additive   **--**       **--**            **--**   0.85 (0.71**--**1.02)   0.080       **--**   **0.81 (0.67--0.98)**   **0.027**
  rs485842    Allele         C            714               868      1                                   668      1                       
                             T            286               282      **0.81 (0.67--0.98)**   **0.032**   228      0.85 (0.70**--**1.04)   0.123
              Genotype       CC           258               326      1                                   250      1                       
                             CT           198               216      0.86 (0.67**--**1.11)   0.253       168      0.88 (0.67**--**1.15)   0.347
                             TT           44                33       **0.59 (0.37--0.96)**   **0.033**   30       0.69 (0.42**--**1.13)   0.138
              Dominant       CC           258               326      1                                   250      1                       
                             CT-TT        242               249      0.81 (0.64**--**1.04)   0.094       198      0.84 (0.65**--**1.09)   0.192
              Recessive      CC-CT        456               542      1                                   418      1                       
                             TT           44                33       0.63 (0.39**--**1.01)   0.054       30       0.72 (0.45**--**1.18)   0.192
              Log-additive   **--**       **--**            **--**   **0.81 (0.67--0.98)**   **0.033**   **--**   0.85 (0.69**--**1.04)   0.116

*P*-values were calculated by logistic regression analysis with adjustments for age and gender.

*P*\<0.05 means the data are statistically significant.

Bold means the data are statistically significant.

We also conducted stratification analyses by age and gender ([Table 3](#T3){ref-type="table"}), and revealed that the effect of both rs7938889 and rs485842 on glioma risk remained significant. The association between glioma risk and rs7938889 genotypes was more profound in the individuals at age ≤ 40 years (T vs C, OR = 0.75, *P*=0.020; TT vs CC, OR = 0.56, *P*=0.031) and males (TT vs CC, OR = 0.59, *P*=0.032), while rs485842 variant in the subjects at age \> 40 years (T vs C, OR = 0.66, *P*=0.003; TT vs CC, OR = 0.31, *P*=0.0005). Furthermore, we also found that rs7115578 polymorphism had a lower susceptibility to glioma in males (AG-GG vs AA, OR = 0.68, *P*=0.034), while rs4598633 variant was associated with a higher risk for glioma in females (CT vs CC, OR = 1.66, *P*=0.016; CT-TT vs CC, OR = 1.49, *P*=0.043). We further stratified by the glioma grade, and there was a lower prevalence of rs7115578-GG carriers in the high-grade subgroup (WHO III+IV) than in the low-grade subgroup (WHO I+II) (16.99 vs 24.39%) with a marginal *P*-value in recessive model (OR = 0.64, 95% CI: 0.41--1.00, *P*=0.048, Supplementary Table S3), which indicated insufficient evidence for claiming an association and needed further verification.

###### Relationships of *MAML2* polymorphisms with glioma risk stratified by age and gender

  SNP ID       Model          Genotype   Case   Control   OR (95% CI)             *P*          Case   Control   OR (95% CI)             *P*
  ------------ -------------- ---------- ------ --------- ----------------------- ------------ ------ --------- ----------------------- -----------
  rs7938889    Allele         C          330    264       1                                    341    287       1                       
                              T          254    206       0.99 (0.77--1.26)       0.913        217    243       **0.75 (0.59--0.96)**   **0.020**
               Genotype       CC         82     79        1                                    101    71        1                       
                              CT         166    106       1.44 (0.96--2.14)       0.075        139    145       **0.65 (0.44--0.96)**   **0.031**
                              TT         44     50        0.83 (0.50--1.38)       0.473        39     49        **0.56 (0.33--0.95)**   **0.031**
               Dominant       CC         82     79        1                                    101    71        1                       
                              CT-TT      210    156       1.24 (0.85--1.80)       0.265        178    194       **0.63 (0.43--0.91)**   **0.014**
               Recessive      CC-CT      248    185       1                                    240    216       1                       
                              TT         44     50        0.66 (0.42--1.04)       0.073        39     49        0.73 (0.46--1.17)       0.189
               Log-additive   --         --     --        0.97 (0.75--1.25)       0.796        --     --        **0.73 (0.56--0.94)**   **0.016**
  rs485842     Allele         C          458    325       1                                    410    389       1                       
                              T          134    145       **0.66 (0.50--0.86)**   **0.003**    148    141       1.00 (0.76--1.30)       0.976
               Genotype       CC         177    121       1                                    149    137       1                       
                              CT         104    83        0.85 (0.58--1.23)       0.378        112    115       0.93 (0.65--1.33)       0.682
                              TT         15     31        **0.31 (0.16--0.59)**   **0.0005**   18     13        1.35 (0.63--2.89)       0.445
               Dominant       CC         177    121       1                                    149    137       1                       
                              CT-TT      119    144       **0.70 (0.49--0.99)**   **0.043**    130    128       0.97 (0.69--1.37)       0.866
               Recessive      CC-CT      281    204       1                                    261    252       1                       
                              TT         15     31        **0.33 (0.17--0.62)**   **0.001**    18     13        1.39 (0.66--2.94)       0.386
               Log-additive   --         --     --        **0.66 (0.50--0.86)**   **0.002**    --     --        1.03 (0.77--1.37)       0.844
  **Gender**                                              **Male**                                              **Female**              
  rs7938889    Allele         C          382    305       1                                    289    246       1                       
                              T          254    253       0.8 (0.64--1.01)        0.059        217    196       0.94 (0.73--1.22)       0.651
               Genotype       CC         107    83        1                                    76     67        1                       
                              CT         168    139       0.94 (0.65--1.35)       0.729        137    112       1.08 (0.71--1.63)       0.716
                              TT         43     57        **0.59 (0.36--0.96)**   **0.032**    40     42        0.84 (0.49--1.45)       0.53
               Dominant       CC         107    83        1                                    76     67        1                       
                              CT-TT      211    196       0.84 (0.59--1.18)       0.309        177    154       1.01 (0.68--1.5)        0.945
               Recessive      CC-CT      275    222       1                                    213    179       1                       
                              TT         43     57        **0.61 (0.39--0.94)**   **0.025**    40     42        0.80 (0.5--1.29)        0.359
               Log-additive   --         --     --        0.79 (0.62--1.00)       0.054        --     --        0.94 (0.72--1.23)       0.641
  rs7115578    Allele         A          365    289       1                                    262    245       1                       
                              G          275    269       0.81 (0.64--1.02)       0.069        248    197       1.18 (0.91--1.52)       0.211
               Genotype       AA         108    72        1                                    69     69        1                       
                              AG         149    145       0.68 (0.47--1.00)       0.048        124    107       1.16 (0.76--1.77)       0.495
                              GG         63     62        0.68 (0.43--1.07)       0.097        62     45        1.38 (0.83--2.29)       0.217
               Dominant       AA         108    72        1                                    69     69        1                       
                              AG-GG      212    207       **0.68 (0.48--0.97)**   **0.034**    186    152       1.22 (0.82--1.82)       0.319
               Recessive      AA-AG      257    217       1                                    193    176       1                       
                              GG         63     62        0.86 (0.58--1.27)       0.447        62     45        1.26 (0.81--1.94)       0.302
               Log-additive   --         --     --        0.81 (0.65--1.02)       0.071        --     --        1.17 (0.91--1.51)       0.217
  rs4598633    Allele         C          348    295       1                                    283    259       1                       
                              T          290    263       0.93 (0.74--1.17)       0.562        225    183       1.13 (0.87--1.46)       0.370
               Genotype       CC         96     74        1                                    71     81        1                       
                              CT         156    147       0.82 (0.56--1.19)       0.297        141    97        **1.66 (1.1--2.50)**    **0.016**
                              TT         67     58        0.89 (0.56--1.42)       0.624        42     43        1.11 (0.66--1.9)        0.690
               Dominant       CC         96     74        1                                    71     81        1                       
                              CT-TT      223    205       0.84 (0.59--1.20)       0.334        183    140       **1.49 (1.01--2.20)**   **0.043**
               Recessive      CC-CT      252    221       1                                    212    178       1                       
                              TT         67     58        1.01 (0.68--1.50)       0.950        42     43        0.82 (0.51--1.31)       0.408
               Log-additive   ---        ---    ---       0.93 (0.74--1.18)       0.557        ---    ---       1.13 (0.87--1.47)       0.364

*P*-values were calculated by logistic regression analysis with adjustments for age and gender.

*P*\<0.05 means the data are statistically significant.

Bold means the data are statistically significant.

Prognostic value of MAML2 SNPs in glioma patients {#sec3-4}
-------------------------------------------------

Of the 575 patients, 514 patients had complete follow-up data. We evaluated the impact of clinical factors on patients' survival by Log-rank tests and univariate analysis, as shown in Supplementary Table S4 and Figure S3. The extent of resection (gross-total resection) was associated with the OS (log-rank *P*\<0.001, HR = 0.63, *P*\<0.001) and PFS (log-rank *P*\<0.001, HR = 0.59, *P*\<0.001) mortality hazards, respectively. Moreover, chemotherapy was a protective factor in all glioma patients (OS: log-rank *P*\<0.001, HR = 0.67, *P*\<0.001; PFS: log-rank *P*=0.012, HR = 0.81, *P*=0.025).

We investigated the association between *MAML2* polymorphisms and the prognosis of glioma patients using Log-rank tests and univariate Cox regression analysis ([Table 4](#T4){ref-type="table"} and [Figure 1](#F1){ref-type="fig"}). *MAML2* rs7115578 polymorphism was only one that affected the prognosis of glioma in the overall. Compared with the AA carriers of rs7115578, the AG genotype carriage represented a poorer prognosis of glioma (HR = 1.24, 95% CI: 1.02--1.52, *P*=0.033). In astrocytoma, rs7115578 polymorphism also was a predictor for unfavorable prognosis (OS: log-rank *P*=0.037, HR = 1.31, 95% CI: 1.02--1.69, *P*=0.036). We next divided all patients into two groups (low- and high-grade gliomas) according to WHO grade. In patients with low-grade glioma, Kaplan--Meier analyses and univariate analyses revealed that rs11021499-GA genotype had lower OS (log-rank *P*=0.046, HR = 1.30, 95% CI: 1.00--1.68, *P*=0.047) and PFS (log-rank *P*=0.024, HR = 1.33, 95% CI: 1.03--1.72, *P*=0.032) than CC genotype.

![Kaplan--Meier survival curves for MAML2 polymorphism and glioma prognosis\
Kaplan--Meier survival curves for PFS based on *MAML2* rs7115578 in astrocytoma (**A**) and for OS and PFS based on *MAML2* rs11021499 polymorphism in low-grade glioma (**B,C**).](bsr-39-bsr20192091-g1){#F1}

###### Univariate analysis of the association between *MAML2* polymorphisms and glioma patient OS and PFS

  SNP ID                         Genotype   OS          PFS                                                                                             
  ------------------------------ ---------- ----------- ------------- ----------------------- ----------- ------- ------------- ----------------------- -----------
  **rs7115578**                  AA         0.052       0.369/0.113   1                                   0.073   0.210/0.117   1                       
                                 AG                     0.276/0.071   **1.24 (1.02--1.52)**   **0.033**           0.160/0.075   1.22 (1.00--1.50)       0.051
                                 GG                     0.336/0.111   1.07 (0.84--1.37)       0.595               0.185/-       1.06 (0.83--1.35)       0.661
  **Astrocytoma**                                                                                                                                       
  **rs7115578**                  AA         **0.037**   0.395/0.055   1                                   0.093   0.206/0.072   1                       
                                 AG                     0.236/0.065   **1.31 (1.02--1.69)**   **0.036**           0.145/0.069   1.25 (0.97--1.61)       0.085
                                 GG                     0.362/0.112   1.02 (0.75--1.38)       0.909               0.200/0.129   1.01 (0.74--1.37)       0.971
  **Low-grade glioma (I--II)**                                                                                                                          
  **rs11021499**                 GG         **0.046**   0.406/0.127   1                                   0.024   0.245/0.142   1                       
                                 GA                     0.274/0.075   **1.30 (1.00--1.68)**   **0.047**           0.147/-       **1.33 (1.03--1.72)**   **0.032**
                                 AA                     0.345/-       1.02 (0.75--1.40)       0.885               0.214/-       1.02 (0.75--1.40)       0.883

Abbreviation: SR, survival rate.

Log-rank *P*-values were calculated using the Chi-Square test.

*P*\<0.05 indicates statistical significance.

We next interrogated the association between *MAML2* SNPs and PFS or OS by a multivariate Cox proportional hazard model, adjusted for patient surgical method and chemotherapy ([Table 5](#T5){ref-type="table"}). The rs7115578 heterozygous was significantly associated with the poorer PFS of glioma (HR = 1.25, 95% CI: 1.02--1.53, *P*=0.031) and high-grade glioma (HR = 1.45, 95% CI: 1.03--2.03, *P*=0.032). Additionally, astrocytoma patients carrying the AG genotype had significantly decreased OS (HR = 1.40, 95% CI: 1.08--1.81, *P*=0.010) and PFS (HR = 1.38, 95% CI: 1.07--1.78, *P*=0.014) compared with those with the AA genotype.

###### Multivariate analysis of the association between *MAML2* rs7115578 polymorphism and glioma patient OS and PFS

  SNP ID                        Genotype   OS                      PFS                                 
  ----------------------------- ---------- ----------------------- ----------- ----------------------- -----------
  rs7115578                     AA         1                                   1                       
                                AG         1.21 (1.00--1.49)       0.056       **1.25 (1.02--1.53)**   **0.031**
                                GG         1.06 (0.83--1.36)       0.627       1.07 (0.84--1.37)       0.572
  Astrocytoma                                                                                          
  rs7115578                     AA         1                                   1                       
                                AG         **1.40 (1.08--1.81)**   **0.010**   **1.38 (1.07--1.78)**   **0.014**
                                GG         1.17 (0.86--1.60)       0.306       1.19 (0.87--1.61)       0.275
  High-grade glioma (III--IV)                                                                          
  rs7115578                     AA         1                                   1                       
                                AG         1.35 (0.96--1.89)       0.080       **1.45 (1.03--2.03)**   **0.032**
                                GG         1.27 (0.81--1.98)       0.297       1.28 (0.82--1.99)       0.284

Log-rank *P*-values were calculated using the Chi-Square test.

*P*-values were calculated by Cox multivariate analysis with adjustments for surgical method and use of chemotherapy.

*P*\<0.05 indicates statistical significance.

Discussion {#sec4}
==========

In the present study, we first investigated the association between *MAML2* genetic variants and glioma risk or prognosis among the Chinese Han population. We found that rs7938889, rs485842, rs7115578 and rs4598633 polymorphisms were significantly related to the risk of glioma. Moreover, we demonstrated that rs7115578 and rs11021499 variants represented a poorer prognosis of glioma. To the best of our knowledge, no previous studies have investigated the role of *MAML2* variants for glioma. Our study addressed a gap in knowledge of the *MAML2* gene polymorphisms and the susceptibility and prognosis of glioma, indicating that *MAML2* genetic variations might play an important role in the development of glioma.

MAML2, located at 11q21, normally acts as a co-activator of Notch receptor and transactivates Notch target gene, participating in the formation of Notch-associated RBP-J/CBF complex \[[@B19],[@B20]\]. The oncogenic role of *MAML2* was first described in mucoepidermoid carcinoma, in which a fusion oncogene *MECT1-MAML2* that was involved in disrupting the normal cell cycle, differentiation and tumor development \[[@B21]\]. In addition, *MAML2* was previously found to participate in a fusion with *CRTC1*, which was important for cell growth, proliferation, survival, migration and metabolism \[[@B22]\]. These studies provided some biologic evidence for the role played by *MAML2* in possible molecular mechanisms of carcinogenesis. A recent study showed that the *CRTC1-MAML2* gene fusion was also identified in the brain tumors \[[@B23]\]. Additionally, *MAML2* as a novel gene was abnormal expressed in glioma \[[@B14]\]. By bioinformatics analysis, we found that *MAML2* gene expression is up-regulated in glioma compared with normal tissue. Moreover, low expression of *MAML2* was associated with a poor OS for glioma, especially lower grade glioma. These results hinted that *MAML2* plays an important role in the progression and prognosis of glioma, but more studies are needed to validate.

Previous studies have confirmed that the genetic variability of *MAML2*, including structural variation, copy number variation and SNPs, were associated with the occurrence and progression of disease \[[@B16],[@B24],[@B25]\]. In the present study, four SNPs in *MAML2* (rs7938889 and rs485842, rs7115578 and rs4598633) were found to be significantly associated with glioma risk. Specifically, carriers of the rs7938889 TT and rs485842 TT genotypes reduced the risk of the overall glioma and astrocytoma. Furthermore, the association between glioma risk and rs7938889 genotypes was more profound in the individuals at age ≤ 40 years, while rs485842 variant in the subjects at age \> 40 years. We also found that rs7938889 and rs7115578 polymorphisms had a lower susceptibility to glioma in males, while rs4598633 variant was associated with a higher risk for glioma in females. There are differences of glioma incidence in gender and age \[[@B26]\]. This result suggested the risk association of *MAML2* polymorphisms with glioma might be dependent on age or gender. More importantly, we revealed that rs7115578 AG genotype represented a poorer prognosis of glioma, particularly among astrocytoma and high-grade glioma. Rs11021499 polymorphism had lower OS and PFS in patients with low-grade glioma. Although *MAML2* polymorphisms were found to be significantly associated with the risk and prognosis of glioma, the mechanism of *MAML2* underlying the effect on the glioma risk and patients survival was not identified in the present study, nor has not been reported in the literature. Several studies supported that intronic SNPs confer susceptibilities by affecting gene expression \[[@B27]\]. The online prediction tool Haploreg showed that rs7938889 and rs485842, rs7115578, rs4598633 and rs11021499 polymorphisms, located in the intron region, were associated with the regulation of promoter histone marks, enhancer histone marks, DNAse and/or motifs changed, suggesting their possible functions in glioma patients. However, further study is necessary to confirm the function of these variant in glioma.

Strengths of the current study include the relatively large sample size considering the rarity of glioma, and the first demonstration on the associations of *MAML2* polymorphisms with glioma risk and prognosis among Chinese Han population. However, several limitations should be addressed in the present study. First, the potential selection bias might have occurred because the study subjects in our study were hospital-based, thus the conclusion of the present study warrants further confirmation in a larger scale population. Second, the detailed molecular mechanism under which *MAML2* polymorphisms affect glioma risk and prognosis needs further studies to elucidate.

Conclusion {#sec5}
==========

In conclusion, these results suggested that *MAML2* polymorphisms might contribute to glioma susceptibility and prognosis. We found that *MAML2* rs7938889 and rs485842 polymorphisms were significantly associated with the reduced risk of glioma. Moreover, rs7115578 seem to confer a worse prognosis for glioma and astrocytoma. Although these data need confirmation by independent studies, our results hint *MAML2* genetic variants might play an important role in the development of glioma among Chinese Han population, and add to the body of knowledge surrounding genetic polymorphisms as putative player affecting the risk or prognosis of glioma.
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